Jazz Pharmaceuticals (FRA:J7Z) Construction In Progress : €16 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Jazz Pharmaceuticals Construction In Progress?

Jazz Pharmaceuticals's quarterly construction in progress declined from Sep. 2023 (€69 Mil) to Dec. 2023 (€17 Mil) and declined from Dec. 2023 (€17 Mil) to Mar. 2024 (€16 Mil).

Jazz Pharmaceuticals's annual construction in progress declined from Dec. 2021 (€77 Mil) to Dec. 2022 (€64 Mil) and declined from Dec. 2022 (€64 Mil) to Dec. 2023 (€17 Mil).

Jazz Pharmaceuticals Construction In Progress Historical Data

The historical data trend for Jazz Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Construction In Progress Chart

Jazz Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

4.63

5.97

76.56

63.61

17.11

Jazz Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Construction In Progress	Get a 7-Day Free Trial															64.63	68.10	68.67	17.11	15.89

Jazz Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Jazz Pharmaceuticals (FRA:J7Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (FRA:J7Z) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

JAZZ:USA JAZZ:Mexico

Address

Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7

Website

https://www.jazzpharmaceuticals.com

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals (FRA:J7Z) Headlines

No Headlines